Loading…
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc (NBIX) is listed on NASDAQ and classified in Drug Manufacturers - Specialty & Generic, part of the Healthcare sector. It is headquartered in San Diego, United States and has 2,500 employees. The company is worth $14.57B and trades at 20.7x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $2.86B in fiscal 2025, up 21.4% from the year before. Net income was $478.6M. The share price is 23.0% below its 52-week high of $186.12. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $643.47M. In that quarter, 1 of them opened or added to the position and 5 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▲ +63.0% over 5Y.
today you would have $1,287.45▲ +28.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $141.83 | $136.50 | $131.76 | $119.44 | $85.17 | $95.85 | $107.49 | $71.41 | $77.59 | $38.70 | $56.57 | $22.34 | $9.34 | $7.48 | $8.50 | $7.64 | $2.72 | |
| P/E |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 2.3% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
Median P/E of 47.4 across this company’s own years on record.
Cash flow growing 2.3% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ICLRIcon PLC | $185.43 | 195.2x | 1.5x | 0.00% | 0.29% | $14.31B |
| SOLVSolventum Corp | $87.45 | 10.6x | 3.1x | 0.00% | 33.96% | $14.89B |
| HALOHalozyme Therapeutics Inc | $124.54 | 36.5x | 98.9x | 0.00% | 173.67% | $14.14B |
| JAZZJazz Pharmaceuticals plc | $214.65 |
| 47.4x |
| 30.4x |
| 41.5x |
| 53.3x |
| 76.6x |
| 92.6x |
| 23.0x |
| 275.6x |
| 324.6x |
| — |
| — |
| — |
| — |
| — |
| 93.5x |
| 12.7x |
| — |
| — |
| P/S | 10.9x | 5.0x | 5.8x | 6.9x | 7.7x | 7.2x | 8.6x | 12.6x | 14.4x | 42.9x | 224.8x | 247.4x | — | 216.9x | 9.4x | 7.3x | 12.5x | 36.0x |
| P/B | 8.3x | 4.4x | 5.3x | 5.9x | 6.8x | 5.9x | 8.0x | 15.6x | 13.5x | 18.6x | 10.7x | 11.5x | 8.3x | 5.3x | 3.2x | 9.4x | 21.7x | 26.9x |
| EPS | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | -$1.62 | -$1.63 | -$1.05 | -$0.81 | -$0.69 | $0.08 | $0.67 | -$0.15 | -$1.30 |
| Profit margin | 6.30% | 16.73% | 14.49% | 13.23% | 10.38% | 7.90% | 38.94% | 4.69% | 4.68% | -88.19% | -940.60% | -449.84% | — | -1578.97% | 9.46% | 48.53% | -23.78% | -1728.34% |
| ROE | 4.39% | 14.71% | 13.18% | 11.19% | 9.05% | 6.52% | 36.17% | 5.81% | 4.39% | -38.30% | -44.81% | -20.95% | -29.01% | -38.28% | 3.26% | 62.53% | -41.19% | -1290.79% |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
6 methods answered, across 3 families.
Room for errors in the reported numbers.
-18.0% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 14.5x |
| 2.9x |
| 0.00% |
| 22.11% |
| $13.93B |
| BBIOBridgeBio Pharma, Inc. | $68.12 | — | — | 0.00% | — | $13.32B |
| ASNDAscendis Pharma A/S | $242.99 | 18.6x | 9.9x | 0.00% | 118.78% | $15.99B |
